Compare · GH vs ILMN
GH vs ILMN
Side-by-side comparison of Guardant Health Inc. (GH) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GH and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.38B, about 1.3x GH ($22.61B).
- Over the past year, GH is up 207.3% and ILMN is up 98.4% - GH leads by 109.0 points.
- GH has been more active in the news (11 items in the past 4 weeks vs 8 for ILMN).
- Both have 25 recent analyst ratings on file.
- Company
- Guardant Health Inc.
- Illumina Inc.
- Price
- $168.45+6.94%
- $188.04-3.07%
- Market cap
- $22.61B
- $28.38B
- 1M return
- +2.62%
- -2.94%
- 1Y return
- +207.33%
- +98.35%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2000
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 25
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest GH
- Director Hidalgo Medina Manuel sold $279,202 worth of shares (1,700 units at $164.24) and exercised 950 shares at a strike of $32.55, decreasing direct ownership by 14% to 4,556 units (SEC Form 4)
- Director Clark Ian T exercised 9,088 shares at a strike of $60.63 and sold $2,253,451 worth of shares (14,180 units at $158.92) (SEC Form 4)
- SEC Form 144 filed by Guardant Health Inc.
- SEC Form S-3ASR filed by Guardant Health Inc.
- SEC Form 10-Q filed by Guardant Health Inc.
- Guardant Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
- Guardant Health to Participate in Upcoming Investor Conferences
- Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer
- Director Mignone Roberto converted options into 264 shares, increasing direct ownership by 3% to 9,746 units (SEC Form 4)
Latest ILMN
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $123,000 worth of shares (615 units at $200.00), decreasing direct ownership by 3% to 20,338 units (SEC Form 4)
- SEC Form 10-Q filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
- SEC Form 3 filed by new insider Sullivan Michael C
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026